Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.
Jorge E RomagueraMichael L WangLei FengLuis E FayadFrederick HagemeisterPeter McLaughlinM Alma RodriguezMichelle FanaleRobert OrlowskiLarry W KwakSattva NeelapuYasuhiro OkiBarbara ProAnas YounesFelipe SamaniegoNathan FowlerKimberly HartigMarisa ValentinettiJudy SmithPeggy FordAdam NaigL Jeffrey MedeirosHagop M KantarjianAndre GoyPublished in: Cancer (2018)
BzR-hyperCVAD/BzR-MA at the dose and schedule studied produced high rates of response and a TTF similar to that of historical reports without bortezomib. Cancer 2018;124:2561-9. © 2018 American Cancer Society.